深部热疗联合重组人血管内皮抑制素注射液及AP方案治疗晚期非小细胞肺癌的近期疗效观察  

Observation on the short-term efficacy of deep hyperthermia combined with recombinant human endostatin injection and AP regimen in the treatment of advanced non-small cell lung cancer

作　　者：李超 肖敬 周红梅[2] LI Chao;XIAO Jing;ZHOU Hong-mei(Department of Oncology,the Seventh People's Hospital of Hebei Province,Dingzhou Hebei 073000,China;Department of Pulmonary Disease,the Seventh People's Hospital of Hebei Province,Dingzhou Hebei 073000,China)

机构地区：[1]河北省第七人民医院肿瘤科,河北定州073000 [2]河北省第七人民医院肺病科,河北定州073000

出　　处：《临床和实验医学杂志》2024年第4期345-349,共5页Journal of Clinical and Experimental Medicine

基　　金：河北省医学科学研究课题(编号:20211795)。

摘　　要：目的探讨深部热疗联合重组人血管内皮抑制素注射液及培美曲塞联合顺铂(AP方案)治疗晚期非小细胞肺癌(NSCLC)的近期疗效。方法回顾性分析2016年1月至2022年1月河北省第七人民医院收治的120例晚期NSCLC患者的相关资料,按照治疗方法不同将患者分为研究组(n=59)和对照组(n=61)。研究组患者采用深部热疗联合重组人血管内皮抑制素注射液及AP方案治疗,对照组患者采用重组人血管内皮抑制素注射液及AP方案。观察两组患者的近期疗效[客观反应率(ORR)、疾病控制率(DCR)],治疗前、治疗后3个月的血清肿瘤标志物[神经元特异性烯醇化酶(NSE)、糖类抗原125(CA125)、细胞角质素片段抗原(Cyfra21-1)及癌胚抗原(CEA)]水平、生活质量评分(KPS)评分]、血常规指标[红细胞计数(RBC)、白细胞计数(WBC)、血小板计数(PLT)]以及不良反应发生情况。结果研究组ORR、DCR分别为15.25%、57.63%,均高于对照组(3.28%、36.07%),差异均有统计学意义(P<0.05)。治疗3个月后,两组NSE、CA125、Cyfra21-1、CEA水平均低于治疗前,且研究组治疗后NSE、CA125、Cyfra21-1、CEA水平分别为(15.23±5.06)ng/mL、(50.16±5.12)U/mL、(6.52±2.03)ng/mL、(30.17±4.17)ng/mL,均低于对照组[(20.16±5.04)ng/mL、(80.24±5.22)U/mL、(10.25±3.09)ng/mL、(60.22±4.17)ng/mL],差异均有统计学意义(P<0.05)。研究组KPS改善率为77.97%,高于对照组(57.38%),差异有统计学意义(P<0.05)。治疗3个月后,两组RBC、WBC、PLT值均较治疗前降低,研究组RBC、WBC、PLT值分别为(3.61±0.12)×10^(12)、(3.98±1.07)×10^(9)、(210.23±30.16)×10^(9),均高于对照组[(3.50±0.11)×10^(12)、(3.12±1.03)×10^(9)、(198.24±20.17)×10^(9)],差异均有统计学意义(P<0.05)。研究组0~Ⅳ级胃肠道不适、肝损伤、肾损伤、贫血不良反应发生率与对照组比较,差异均有统计学意义(P<0.05),研究组各种不良反应的严重程度低于对照组。结论深部热疗联合重组人血Objective To investigate the short-term efficacy of deep hyperthermia combined with recombinant human endostatin injection and pemetrexed combined with cisplatin(AP regimen) in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Retrospective analysis was used on the relevant data of 120 patients with advanced NSCLC admitted to the Seventh People's Hospital of Hebei Province from January 2016 to January 2021.They were divided into the study group(n=59) and the control group(n=61) according to different treatment methods.The patients in the study group were treated with deep hyperthermia combined with recombinant human endostatin injection and AP regimen,while the patients in the control group were treated with recombinant human endostatin injection and AP regimen.The short-term efficacy[objective response rate(ORR),disease control rate(DCR)],serum tumor markers[neuron specific enolase(NSE),carbohydrate antigen(CA125),cytokinin fragment antigen(Cyfra21-1),and carcinoembryonic antigen(CEA)] levels,quality of life score [karnofsky performance status(KPS) score],blood routine indicators[red blood cells count(RBC),white blood cells count(WBC),platelets count(PLT)] before and 3 months after treatment,and adverse reactions of two groups of patients were observed.Results The ORR and DCR of the study group were 15.25%,57.63%,which were higher than those of the control group(3.28%,36.07%),the differences were statistically significant(P<0.05).After 3 months of treatment,the levels of NSE,CA125,Cyfra21-1,and CEA in two groups were lower than those before treatment,and the levels of NSE,CA125,Cyfra21-1,and CEA in the study group were(15.23±5.06) ng/mL,(50.16±5.12) U/mL,(6.52±2.03) ng/mL,(30.17±4.17) ng/mL,respectively,which were lower than those in the control group [(20.16±5.04) ng/mL,(80.24±5.22) U/mL,(10.25±3.09) ng/mL,(60.22±4.17) ng/mL],the differences were statistically significant(P<0.05).The improvement rate of KPS in the study group was 77.97%,which was higher than that in the control group(5

关 键 词：非小细胞肺癌 深部热疗 重组人血管内皮抑制素注射液 AP方案 近期疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]